Form 4: Dyne Therapeutics CEO Granted Performance-Based Stock Options

Dyne Therapeutics, Inc. CEO John Cox received a grant of 197,285 performance-based stock options with an exercise price of $9.33, contingent on the company's stock reaching $20.00.

Summary

• John Cox, CEO & President and Director of Dyne Therapeutics, Inc. (DYN), was granted 197,285 stock options on July 16, 2025.
• The options have an exercise price of $9.33 per share and are set to expire on July 15, 2035.
• Vesting occurs over three years, with 50% of the shares underlying the grant vesting 18 months after the July 16, 2025 grant date, and the balance vesting in equal quarterly installments thereafter.
• The options are exercisable only if the average closing price of Dyne Therapeutics common stock on the Nasdaq Global Select Market equals or exceeds $20.00 per share over a 20 consecutive trading day period at any time during the three-year period following the grant date.
• Alternatively, the options become exercisable if a Change in Control is consummated during the three-year performance period, where a third party acquires the common stock for a price per share that the Board of Directors determines equals or exceeds $20.00 per share.

Sentiment

Score: 7

Explanation: The grant of performance-based stock options to the CEO aligns management incentives with shareholder value creation, indicating a positive outlook on future stock performance and a commitment to long-term growth. The performance hurdle suggests confidence in achieving significant milestones.

Positives

• The grant of performance-based stock options directly aligns the CEO's incentives with long-term shareholder value creation.
• The $20.00 per share performance hurdle demonstrates management's confidence in achieving significant stock price appreciation.
• The long expiration date of July 15, 2035, provides a substantial window for the performance conditions to be met and for the options to be exercised.

Negatives

• The options are not immediately exercisable and are subject to challenging performance conditions, meaning they may not vest or become exercisable if the stock price targets are not met.

Risks

• The primary risk is that the company's stock price may not reach the $20.00 per share performance threshold within the three-year performance period, rendering the options unexercisable.
• Market volatility and general economic conditions could impact the company's ability to achieve the required stock price.

Future Outlook

The grant of performance-based stock options with a $20.00 per share target suggests management's internal outlook anticipates significant future stock price appreciation for Dyne Therapeutics within the next three years.

Industry Context

Performance-based equity compensation, particularly stock options with specific price hurdles, is a common practice in the biotechnology and pharmaceutical sectors. This approach is used to incentivize executive leadership to achieve significant milestones and drive long-term shareholder value, reflecting the high-risk, high-reward nature of drug development and commercialization.

Comparison to Industry Standards

• Performance-based equity grants are a standard incentive mechanism across growth-oriented industries, including biotech.
• Companies like Moderna (MRNA) and BioNTech (BNTX) have utilized similar structures to align executive compensation with clinical trial successes and commercialization milestones, which often translate to significant stock price movements.
• The specific $20.00 per share target for Dyne Therapeutics is tailored to its current valuation and growth trajectory, aiming for a substantial increase from the $9.33 exercise price, which is a common spread seen in early to mid-stage biotech companies aiming for significant market capitalization growth.

Corporate Governance

Related Party Transactions

• The stock option grant to John Cox, the CEO and a Director, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company achieves the stock price performance targets, as the CEO's incentives are aligned with this outcome.
• Management: Strong incentive to drive stock price appreciation to meet the performance hurdles and realize value from the options.

Next Steps

• Dyne Therapeutics' management will focus on achieving operational and strategic goals to drive the stock price to or above $20.00 per share.
• The company will continue to execute its business plan to meet the vesting and exercisability conditions of the granted options.

Key Dates

Recommendation

Keywords

Dyne Therapeutics, DYN, John Cox, Stock Option, Performance-Based Equity, CEO Compensation, Executive Incentive, Nasdaq, Biotech, Pharmaceutical